Institutional experience on the impact of glucagon-like peptide-1 agonists (GLP-1) on glycemic control and weight loss in patients with type 2 diabetes at the Dubai Diabetes Center, United Arab Emirates.

Abdelmannan D, AlBuflasa M, Ajlouni H, Zidan M, Rahman F, Farooqi MH, Enrique Caballero A

Diabetes research and clinical practice7 Dec 2023Cited by 4 (Europe PMC)

PMID38070546DOI10.1016/j.diabres.2023.111045PepBankPUB-38070546

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with T2D, pooled GLP-1 agonist therapy was linked to statistically significant but not clinically significant initial HbA1c reduction.
In plain wordsIn patients with T2D, initial HbA1c fell from baseline with pooled GLP-1 agonists, but the change was not clinically significant.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseInitial HbA1c change
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The study shows that while there was significant reduction in HbA1c and weight in the first 3 months, this change was not clinically significant.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective audit of patients diagnosed Type 2 diabetes receiving one of the three following GLP-1 agonists (Exenatide LA 2 mg weekly, liraglutide 1.8 mg once daily, Dulaglutide 1.5 mg) over one year and documenting changes in HbA1c and weight at 3-, 6-, 9-, and 12-months intervals.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3807054601
02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with T2D, pooled GLP-1 agonist therapy was linked to statistically significant but not clinically significant initial HbA1c reduction.
In plain wordsIn patients with T2D, initial HbA1c fell from baseline with pooled GLP-1 agonists, but the change was not clinically significant.
Peptide
Liraglutide
Outcome
DecreaseInitial HbA1c change
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The study shows that while there was significant reduction in HbA1c and weight in the first 3 months, this change was not clinically significant.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective audit of patients diagnosed Type 2 diabetes receiving one of the three following GLP-1 agonists (Exenatide LA 2 mg weekly, liraglutide 1.8 mg once daily, Dulaglutide 1.5 mg) over one year and documenting changes in HbA1c and weight at 3-, 6-, 9-, and 12-months intervals.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3807054602
03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with T2D, pooled GLP-1 agonist therapy was linked to statistically significant but not clinically significant initial weight reduction.
In plain wordsIn patients with T2D, initial weight fell from baseline with pooled GLP-1 agonists, but the change was not clinically significant.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseInitial weight change
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
The study shows that while there was significant reduction in HbA1c and weight in the first 3 months, this change was not clinically significant.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective audit of patients diagnosed Type 2 diabetes receiving one of the three following GLP-1 agonists (Exenatide LA 2 mg weekly, liraglutide 1.8 mg once daily, Dulaglutide 1.5 mg) over one year and documenting changes in HbA1c and weight at 3-, 6-, 9-, and 12-months intervals.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3807054603
04HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with T2D, pooled GLP-1 agonist therapy was linked to statistically significant but not clinically significant initial weight reduction.
In plain wordsIn patients with T2D, initial weight fell from baseline with pooled GLP-1 agonists, but the change was not clinically significant.
Peptide
Liraglutide
Outcome
DecreaseInitial weight change
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
The study shows that while there was significant reduction in HbA1c and weight in the first 3 months, this change was not clinically significant.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective audit of patients diagnosed Type 2 diabetes receiving one of the three following GLP-1 agonists (Exenatide LA 2 mg weekly, liraglutide 1.8 mg once daily, Dulaglutide 1.5 mg) over one year and documenting changes in HbA1c and weight at 3-, 6-, 9-, and 12-months intervals.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3807054604
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with T2D receiving pooled GLP-1 agonists, the initial HbA1c reduction was not maintained at year end.
In plain wordsIn patients with T2D receiving pooled GLP-1 agonists, the initial HbA1c reduction was not maintained at year end.
Peptide
Dulaglutide (Trulicity)
Outcome
MixedSustainability of HbA1c reduction
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Also, the change was not maintained at the end of the year.
2 context sentences(design, population, supporting numbers)
Summary · context
The study shows that while there was significant reduction in HbA1c and weight in the first 3 months, this change was not clinically significant.
Summary · context
A retrospective audit of patients diagnosed Type 2 diabetes receiving one of the three following GLP-1 agonists (Exenatide LA 2 mg weekly, liraglutide 1.8 mg once daily, Dulaglutide 1.5 mg) over one year and documenting changes in HbA1c and weight at 3-, 6-, 9-, and 12-months intervals.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3807054605
06HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with T2D receiving pooled GLP-1 agonists, the initial HbA1c reduction was not maintained at year end.
In plain wordsIn patients with T2D receiving pooled GLP-1 agonists, the initial HbA1c reduction was not maintained at year end.
Peptide
Liraglutide
Outcome
MixedSustainability of HbA1c reduction
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Also, the change was not maintained at the end of the year.
2 context sentences(design, population, supporting numbers)
Summary · context
The study shows that while there was significant reduction in HbA1c and weight in the first 3 months, this change was not clinically significant.
Summary · context
A retrospective audit of patients diagnosed Type 2 diabetes receiving one of the three following GLP-1 agonists (Exenatide LA 2 mg weekly, liraglutide 1.8 mg once daily, Dulaglutide 1.5 mg) over one year and documenting changes in HbA1c and weight at 3-, 6-, 9-, and 12-months intervals.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3807054606
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with T2D receiving pooled GLP-1 agonists, weight partially returned by the final quarter.
In plain wordsIn patients with T2D receiving pooled GLP-1 agonists, weight partially returned compared with earlier weight loss.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseWeight regain
Study
n: not reported in source
Comparator
Earlier weight loss
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
By the final quarter, the effect of the medication diminishes, accompanied by a partial regain of weight.
2 context sentences(design, population, supporting numbers)
Summary · context
Also, the change was not maintained at the end of the year.
Summary · context
A retrospective audit of patients diagnosed Type 2 diabetes receiving one of the three following GLP-1 agonists (Exenatide LA 2 mg weekly, liraglutide 1.8 mg once daily, Dulaglutide 1.5 mg) over one year and documenting changes in HbA1c and weight at 3-, 6-, 9-, and 12-months intervals.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3807054607
08HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In patients with T2D receiving pooled GLP-1 agonists, weight partially returned by the final quarter.
In plain wordsIn patients with T2D receiving pooled GLP-1 agonists, weight partially returned compared with earlier weight loss.
Peptide
Liraglutide
Outcome
IncreaseWeight regain
Study
n: not reported in source
Comparator
Earlier weight loss
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
By the final quarter, the effect of the medication diminishes, accompanied by a partial regain of weight.
2 context sentences(design, population, supporting numbers)
Summary · context
Also, the change was not maintained at the end of the year.
Summary · context
A retrospective audit of patients diagnosed Type 2 diabetes receiving one of the three following GLP-1 agonists (Exenatide LA 2 mg weekly, liraglutide 1.8 mg once daily, Dulaglutide 1.5 mg) over one year and documenting changes in HbA1c and weight at 3-, 6-, 9-, and 12-months intervals.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3807054608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.